Novartis's Gilenya secures US approval for MS
This article was originally published in Scrip
Executive Summary
Novartis's Gilenya (fingolimod) has become the first oral treatment for multiple sclerosis (MS) in the US that reduces relapses and can slow the progression of disability, after the drug was granted FDA approval.